# ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

> **NCT04247542** · PHASE2 · COMPLETED · sponsor: **Acurx Pharmaceuticals Inc.** · enrollment: 53 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** Ibezapolstat
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT04247542
- **Lead sponsor:** Acurx Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-06
- **Primary completion:** 2023-10-03
- **Final completion:** 2023-11-15
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04247542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04247542, "ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04247542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*